Published on October 29, 2009 at 5:02 AM
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.
The Essure® procedure now has 12 accepted abstracts at ESGE from presenters across Europe recognizing the procedure as the Gold Standard for hysteroscopic sterilization. Among these is an oral presentation by Dr. T. Justin Clark, MRCOG, of the Birmingham Women’s Hospital. On October 30 he will be presenting his abstract entitled, “Essure® Permanent Birth Control: Worldwide Experience 2000 to 2009.” The abstract will focus on the clinical efficacy of Essure®, zero pregnancies in clinical studies and the 94.6% bilateral placement rate of the device.
“I am very pleased to share my success in treating over 200 patients with this highly effective and safe device and believe that the Essure® procedure is the gold standard in treating all patients seeking permanent sterilization,” commented Dr. Clark. “The Essure® device is the most effective, safe and convenient method of female sterilization available, and should be offered to all women seeking permanent contraception.”
The Essure® procedure is the only procedure on the market to have zero pregnancies in clinical trials and more than 100,000 women throughout Europe relying on the device.
SOURCE Conceptus, Inc.